US-based biopharmaceutical company Abeona Therapeutics has obtained the European regulatory approval for its Phase I/II gene therapy clinical trial of ABO-102 (AAV-SGSH) to treat Sanfilippo syndrome type A (MPS IIIA).

ABO-102 has been designed as a gene therapy based on an adeno-associated viral (AAV) indicated to be used to treat MPS IIIA (Sanfilippo syndrome).

It is delivered as a normal copy of the defective gene (SGSH) through an intravenous injection for a single time to deliver to the cells of the central nervous system (CNS) and peripheral organs, in order to correct the genetic errors triggering the disease.

The Phase I/II gene therapy clinical trial is planning to involve 25 patients with MPS III.

"These gene therapies are delivered as a single, non-invasive intravenous injection and offer a new and promising treatment paradigm for patients with this relentless disease."

It has been designed to assess the neurocognitive evaluations, biochemical assays and MRI data produced by the gene therapy after observing the subjects for a year.

Spain's Cruces University Hospital department of paediatrics paediatrician Luis Aldámiz-Echevarría said: "Sanfilippo syndromes are devastating and progressive lysosomal storage diseases that affect children around the world.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“These gene therapies are delivered as a single, non-invasive intravenous injection and offer a new and promising treatment paradigm for patients with this relentless disease.

The preclinical trial earned the approval, during which a single dose of ABO-102 released cells in the CNS and peripheral organs to produce the missing enzyme, and also repaired the cell pathology that had caused the disease.

It also demonstrated safety and early biopotency signals in two low dose patients during an ongoing US trial.